HK inno.N Corporation

KOSDAQ:A195940 Stock Report

Market Cap: ₩1.2t

HK inno.N Valuation

Is A195940 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A195940 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: A195940 (₩41250) is trading above our estimate of future cash flow value (₩11191.96)

Significantly Below Future Cash Flow Value: A195940 is trading above our estimate of future cash flow value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A195940?

Key metric: As A195940 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A195940. This is calculated by dividing A195940's market cap by their current book value.
What is A195940's PB Ratio?
PB Ration/a
Book₩1.16t
Market Cap₩1.17t

Price to Book Ratio vs Peers

How does A195940's PB Ratio compare to its peers?

The above table shows the PB ratio for A195940 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.9x
A039200 Oscotec
8.1x47.05%₩1.5t
A069620 Daewoong Pharmaceutical
1.3x-6.57%₩1.4t
A185750 Chong Kun Dang Pharmaceutical
0.9x4.66%₩885.4b
A086450 DongKook Pharmaceutical
1.2x15.09%₩812.0b
A195940 HK inno.N
n/a17.82%₩1.2t

Price-To-Book vs Peers: Insufficient data to calculate A195940's Price-To-Book Ratio vs. peers for valuation analysis.


Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data


Price to Book Ratio vs Industry

How does A195940's PB Ratio compare vs other companies in the KR Pharmaceuticals Industry?

0 CompaniesPrice / BookEstimated GrowthMarket Cap
A195940 is unprofitableIndustry Avg. 0.8xNo. of Companies16PB00.61.21.82.43+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: Insufficient data to calculate A195940's Price-To-Book Ratio vs. industry for valuation analysis.


Price to Book Ratio vs Fair Ratio

What is A195940's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A195940 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A195940's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A195940 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩41,250.00
₩64,916.67
+57.37%
8.35%₩70,000.00₩55,000.00n/a12
Aug ’27₩36,100.00
₩65,500.00
+81.44%
9.54%₩77,000.00₩55,000.00n/a12
Jul ’27₩41,550.00
₩68,636.36
+65.19%
4.36%₩75,000.00₩64,000.00n/a11
Jun ’27₩43,650.00
₩68,916.67
+57.88%
4.37%₩75,000.00₩64,000.00n/a12
May ’27₩52,400.00
₩68,916.67
+31.52%
4.37%₩75,000.00₩64,000.00n/a12
Apr ’27₩50,700.00
₩66,846.15
+31.85%
6.29%₩72,000.00₩58,000.00n/a13
Mar ’27₩54,000.00
₩66,846.15
+23.79%
6.29%₩72,000.00₩58,000.00n/a13
Feb ’27₩56,300.00
₩66,461.54
+18.05%
6.21%₩72,000.00₩58,000.00n/a13
Jan ’27₩49,300.00
₩65,416.67
+32.69%
7.37%₩72,000.00₩58,000.00n/a12
Dec ’26₩52,700.00
₩65,416.67
+24.13%
7.37%₩72,000.00₩58,000.00n/a12
Nov ’26₩49,400.00
₩65,416.67
+32.42%
7.37%₩72,000.00₩58,000.00n/a12
Oct ’26₩44,750.00
₩62,636.36
+39.97%
8.00%₩70,000.00₩55,000.00n/a11
Sep ’26₩47,100.00
₩62,363.64
+32.41%
8.55%₩70,000.00₩55,000.00n/a11
Aug ’26₩44,800.00
₩62,250.00
+38.95%
8.22%₩70,000.00₩55,000.00₩36,100.0012
Jul ’26₩42,600.00
₩60,916.67
+43.00%
9.10%₩70,000.00₩53,000.00₩41,550.0012
Jun ’26₩41,700.00
₩59,916.67
+43.69%
10.34%₩70,000.00₩50,000.00₩43,650.0012
May ’26₩40,300.00
₩59,916.67
+48.68%
10.34%₩70,000.00₩50,000.00₩52,400.0012
Apr ’26₩37,050.00
₩59,384.62
+60.28%
10.12%₩70,000.00₩49,000.00₩50,700.0013
Mar ’26₩36,000.00
₩59,384.62
+64.96%
10.12%₩70,000.00₩49,000.00₩54,000.0013
Feb ’26₩35,500.00
₩60,923.08
+71.61%
10.33%₩70,000.00₩49,000.00₩56,300.0013
Jan ’26₩35,850.00
₩62,076.92
+73.16%
10.77%₩70,000.00₩49,000.00₩49,300.0013
Dec ’25₩38,400.00
₩62,769.23
+63.46%
10.16%₩70,000.00₩49,000.00₩52,700.0013
Nov ’25₩47,050.00
₩64,307.69
+36.68%
14.86%₩90,000.00₩49,000.00₩49,400.0013
Oct ’25₩48,850.00
₩57,636.36
+17.99%
10.63%₩70,000.00₩49,000.00₩44,750.0011
Sep ’25₩48,000.00
₩54,727.27
+14.02%
6.04%₩61,000.00₩49,000.00₩47,100.0011
Aug ’25₩40,100.00
₩54,583.33
+36.12%
5.72%₩61,000.00₩49,000.00₩44,800.0012
₩64.92k
Fair Value
36.5% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/19 02:34
End of Day Share Price 2026/08/19 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HK inno.N Corporation is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dae Woong YooBookook Securities Co. Ltd
Jisoo LeeDAOL Investment & Securities Co., Ltd.
Myung Sun LeeDB Financial Investment Co. Ltd.